Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[123I]I-(HE)3-G3
- Development stage
- Phase 1
- Lead developer
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[123I]I-(HE)3-G3 is a diagnostic radiopharmaceutical designed for molecular imaging of HER2 expression in breast cancer. It consists of a Designed Ankyrin Repeat Protein (DARPin), specifically the G3 variant with an N-terminal (HE)₃ tag, labeled with radioactive iodine-123. The drug binds to the human epidermal growth factor receptor 2 (HER2), enabling non-invasive visualization and quantification of HER2 expression in tumors using single-photon emission computed tomography (SPECT). This approach aids in patient stratification and monitoring response to therapy for both HER2-positive and HER2-negative breast cancers. The agent was developed by Tomsk National Research Medical Center of the Russian Academy of Sciences and is currently being evaluated in Phase 1 clinical trials for its safety, biodistribution, and imaging efficacy in patients with primary breast cancer[1][5][8].
- Other names
- (HE)3-G3G3 DARPinG-3 DARPinG 3 DARPinradiolabelled (HE)3-G3
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on [123I]I-(HE)3-G3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [123I]I-(HE)3-G3.